DVT and pulmonary embolism linked to immune diseases
07 Jan 2011
Patients with certain immune-mediated diseases may be at increased risk of developing venous thromboembolism (VTE) during hospital stays, according to new research published in BioMed Central's open access journal BMC Medicine.
By analyzing patient records collected over a period of 45 years, researchers at the University of Oxford believe that they may have found a link between those suffering from immune diseases such as rheumatoid arthritis and later development or death from VTE conditions including deep vein thrombosis (DVT) and pulmonary embolism (PE).
Researchers examined the medical records of patients with no evidence or history of VTE who had gone into hospital because of their immune-mediated disease. The patients were grouped according to their condition, for example those with Type 1 diabetes, inflammatory bowel disease or systemic lupus. These cohorts were each compared to a reference group of people who had gone into hospital with minor, non-immune-related conditions (broken bones, minor surgical procedures and so on). The researchers looked to see whether the patients in each cohort then developed VTE, and calculated a "rate ratio" that indicated the likelihood of this happening in each cohort within 90 days or after 90 days of initial hospitalization.
Speaking about the results of the study, principal investigator Dr. Michael Goldacre said, "We found significantly elevated rate ratios of VTE in people with certain immune diseases, particularly those with systemic lupus erythematosus and polyarteritis nodosa, but also in a number of other inflammatory diseases. People who have had surgery are at a greater risk of developing VTE anyway, but those with underlying immune conditions seem to have an even higher risk than the general population".
Though further research is needed to investigate the link between VTE and individual immune disorders, an early explanation for these findings may be that the inflammation caused by the immune response affects the tendency of blood to clot. If this is true, then it may be prudent for certain patients to be given anti-clotting drugs to protect them from VTE while hospitalized.
Head of Public Relations, BioMed Central
Tel: +44 (0) 20 3192 2216
Mob: +44 (0) 7825 257423
Notes to Editors
Risk of venous thromboembolism in people admitted to hospital with selected immune-mediated diseases: record-linkage study
Sreeram V Ramagopalan, Clare J Wotton, Adam E Handel, David Yeates and Michael J Goldacre
BMC Medicine (in press)
Article available at journal website
Please name the journal in any story you write. If you are writing for the web, please link to the article. All articles are available free of charge, according to BioMed Central's open access policy.
Article citation and URL available on request at firstname.lastname@example.org on the day of publication.
BMC Medicine - the flagship medical journal of the BMC series - publishes original research articles, commentaries and reviews in all areas of medical science and clinical practice. To be appropriate for BMC Medicine, articles need to be of outstanding quality, broad interest and special importance. BMC Medicine (ISSN 1741-7015) is indexed/tracked/covered by PubMed, MEDLINE, BIOSIS, CAS, EMBASE, Scopus, Current Contents, Thomson Reuters (ISI) and Google Scholar.
- BioMed Central (http://www.biomedcentral.com/) is an STM (Science, Technology and Medicine) publisher which has pioneered the open access publishing model. All peer-reviewed research articles published by BioMed Central are made immediately and freely accessible online, and are licensed to allow redistribution and reuse. BioMed Central is part of Springer Science+Business Media, a leading global publisher in the STM sector.